BACKGROUND: Enumeration of circulating tumor cells (CTC) from whole blood permits monitoring of patients with breast carcinoma. Analysis of apoptosis & Bcl-2 expression in CTC might add additional prognostic and predictive information. We estimated the degree of these markers in CTC from patients being treated for metastatic breast cancer. METHODS: Eighty-three evaluable patients initiating a new therapy for metastatic breast cancer were enrolled. Whole blood was collected at baseline, at one of three short term time windows (24, 48, or 72 h) after initiating treatment, and at first follow-up (3-5 weeks). CTC were isolated, enumerated, and expression of M30 and Bcl2 was determined using the CellSearch(®) System. RESULTS: At baseline, window, and 3-5 weeks post-treatment, 41/80 (51%), 40/80 (50%) and 21/75 (28%) patients had ≥5 CTC, respectively. At baseline, the proportion of CTC-apoptosis (M30) was inversely correlated with CTC number, and modestly inversely correlated with CTC-Bcl-2. As expected, higher CTC levels at baseline or first follow-up were associated with worse prognosis. Surprisingly, in patients with elevated CTC, higher levels of CTC-apoptosis were associated with worse prognosis, while higher CTC-Bcl-2 levels correlated with better outcomes. CONCLUSIONS: CTC apoptosis and expression of Bcl-2 can be analytically determined in patients with metastatic breast cancer and may have biological and clinical implications. Characterization of CTC for these and other markers could further increase the utility of CTC monitoring patients in clinical investigations of new anti-neoplastic agents.
BACKGROUND: Enumeration of circulating tumor cells (CTC) from whole blood permits monitoring of patients with breast carcinoma. Analysis of apoptosis & Bcl-2 expression in CTC might add additional prognostic and predictive information. We estimated the degree of these markers in CTC from patients being treated for metastatic breast cancer. METHODS: Eighty-three evaluable patients initiating a new therapy for metastatic breast cancer were enrolled. Whole blood was collected at baseline, at one of three short term time windows (24, 48, or 72 h) after initiating treatment, and at first follow-up (3-5 weeks). CTC were isolated, enumerated, and expression of M30 and Bcl2 was determined using the CellSearch(®) System. RESULTS: At baseline, window, and 3-5 weeks post-treatment, 41/80 (51%), 40/80 (50%) and 21/75 (28%) patients had ≥5 CTC, respectively. At baseline, the proportion of CTC-apoptosis (M30) was inversely correlated with CTC number, and modestly inversely correlated with CTC-Bcl-2. As expected, higher CTC levels at baseline or first follow-up were associated with worse prognosis. Surprisingly, in patients with elevated CTC, higher levels of CTC-apoptosis were associated with worse prognosis, while higher CTC-Bcl-2 levels correlated with better outcomes. CONCLUSIONS: CTC apoptosis and expression of Bcl-2 can be analytically determined in patients with metastatic breast cancer and may have biological and clinical implications. Characterization of CTC for these and other markers could further increase the utility of CTC monitoring patients in clinical investigations of new anti-neoplastic agents.
Authors: Songdong Meng; Debasish Tripathy; Eugene P Frenkel; Sanjay Shete; Elizabeth Z Naftalis; James F Huth; Peter D Beitsch; Marilyn Leitch; Susan Hoover; David Euhus; Barbara Haley; Larry Morrison; Timothy P Fleming; Dorothee Herlyn; Leon W M M Terstappen; Tanja Fehm; Thomas F Tucker; Nancy Lane; Jianqiang Wang; Jonathan W Uhr Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Maria Hägg; Kenneth Bivén; Takayuki Ueno; Lars Rydlander; Peter Björklund; Klas G Wiman; Maria Shoshan; Stig Linder Journal: Invest New Drugs Date: 2002-08 Impact factor: 3.850
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Songdong Meng; Debasish Tripathy; Sanjay Shete; Raheela Ashfaq; Barbara Haley; Steve Perkins; Peter Beitsch; Amanullah Khan; David Euhus; Cynthia Osborne; Eugene Frenkel; Susan Hoover; Marilyn Leitch; Edward Clifford; Ellen Vitetta; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Timothy Fleming; Tanja Fehm; Thomas Tucker; Nancy Lane; Jianqiang Wang; Jonathan Uhr Journal: Proc Natl Acad Sci U S A Date: 2004-06-11 Impact factor: 11.205
Authors: Tanja Fehm; Sven Becker; Graziella Becker-Pergola; Karl Sotlar; Gerhard Gebauer; Silke Dürr-Störzer; Hans Neubauer; Diethelm Wallwiener; Erich-Franz Solomayer Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Costanza Paoletti; Yufeng Li; Maria C Muñiz; Kelley M Kidwell; Kimberly Aung; Dafydd G Thomas; Martha E Brown; Vandana G Abramson; William J Irvin; Nancy U Lin; Minetta C Liu; Rita Nanda; Julie R Nangia; Anna M Storniolo; Tiffany A Traina; Christos Vaklavas; Catherine H Van Poznak; Antonio C Wolff; Andres Forero-Torres; Daniel F Hayes Journal: Clin Cancer Res Date: 2015-03-16 Impact factor: 12.531
Authors: Jeffrey B Smerage; G Thomas Budd; Gerald V Doyle; Marty Brown; Costanza Paoletti; Maria Muniz; M Craig Miller; Madeline I Repollet; David A Chianese; Mark C Connelly; Leon W W M Terstappen; Daniel F Hayes Journal: Mol Oncol Date: 2013-03-14 Impact factor: 6.603
Authors: Trevor T Price; Monika L Burness; Ayelet Sivan; Matthew J Warner; Renee Cheng; Clara H Lee; Lindsey Olivere; Karrie Comatas; John Magnani; H Kim Lyerly; Qing Cheng; Chad M McCall; Dorothy A Sipkins Journal: Sci Transl Med Date: 2016-05-25 Impact factor: 17.956